Key result
First Nations peoples with CHD receive similar secondary prevention medications compared to non-indigenous Australians.
Why the study?
Coronary heart disease is the primary cause of mortality in Australia and the largest contributor to the gap in cardiovascular disease deaths between First Nations people and non-indigenous Australians.
Do First Nations people with coronary heart disease receive similar secondary prevention medications and achieve similar clinical targets compared to non-indigenous Australians in primary care?
Cohort (n=50,088)
Yes
Do First Nations people with coronary heart disease receive similar secondary prevention medications and achieve similar clinical targets compared to non-indigenous Australians in primary care?
Answers are grounded in this paper and cite their sources.
While First Nations people with CHD in active primary care receive similar rates of secondary prevention medications compared to non-indigenous Australians, they experience significantly worse achievement of metabolic targets such as HDL-C, triglycerides, and HbA1c.
BACKGROUND: Coronary heart disease (CHD) is the primary cause of mortality in Australia and the largest contributor to the 'gap' in cardiovascular disease deaths between Aboriginal and Torres Strait Islander (First Nations) people and non-indigenous Australians. AIM: To assess secondary prevention of CHD in First Nations people in primary care in Australia. METHODS: Retrospective cohort study of patients with CHD under active primary care management using electronic medical records from 406 general practices across Australia. Ultimately, 50 088 people with CHD were included in the study, and 3.5% of those were First Nations people. After 5.9 years (standard deviation 5.0) in primary care adjusting for gender, age, remoteness, comorbidities, smoking status and continuity of care, First Nations peoples received equal statin (adjusted odds ratio (aOR): 0.9; 95% CI:0.8-1.1, P = 0.28), angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists (aOR:1.0; 95% CI:0.9-1.2, P = 0.85) and beta blockers (aOR:0.9;95% CI:0.8-1.1, P = 0.41) prescriptions. First Nations peoples were more likely to achieve BP <1.8 in similar proportions (35.2% vs 36.9%, P = 0.16) but less likely to have HDL-C >1.0 mmol/L (57.5% vs 73.7%, P < 0.001), triglycerides<2.0 mmol/L (61.7% vs 76.0%, P < 0.001) and HbA1C ≤ 53 mmol/mol (7.0%) (67.7% vs 82.1%, P < 0.001). A higher proportion of First Nations people had HbA1c measured (75.7% vs 66.6%, P < 0.001). CONCLUSION: First Nations peoples with CHD under active primary care management received similar secondary prevention medications and achieved BP and LDL-C targets as frequently as non-indigenous Australians. A focus on easier access to facilitate attending primary care is needed to close the gap as well as addressing social determinants of health and structural inequities.
No takes yet. Share an insight, caveat, or question.
Wing‐Lun et al. (2025) conducted a cohort in Coronary heart disease (CHD) (n=50,088). Aboriginal and Torres Strait Islander (First Nations) status vs. Non-indigenous Australians was evaluated on Statin prescription (aOR 0.9, 95% CI 0.8-1.1, p=0.28). First Nations peoples with CHD received similar secondary prevention medications, including statins, compared to non-indigenous Australians.
Synapse has enriched 10 related papers. Consider them for comparative context: